McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Andrew Williams is quoted in a June 21, 2013 online edition of Life Sciences Intellectual Property Review in an article entitled, “Federal Circuit holds Novo Nordisk patent invalid.” The U.S. Court of Appeals for the Federal Circuit concluded on June 18 that Novo Nordisk’s patent covering diabetes treatment repaglinide is invalid. View the article